The interleukin-1 family: back to the future.
Garlanda C, Dinarello CA, Mantovani A
Immunity. 39(6):1003-18. doi: 10.1016/j.immuni.2013.11.010
Macrophage plasticity and polarization: in vivo veritas.
Sica A, Mantovani A
J Clin Invest. 2012 Mar 1;122(3):787-95. doi: 10.1172/JCI59643
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries CH
Cancer Cell. 2014 Jun 2;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016
RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis.
Strauss L
Cancer Cell. 28(2):253-69. doi: 10.1016/j.ccell.2015.07.006
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
Garassino MC
Cancer Res. 78(20):5729-5730. doi: 10.1158/0008-5472.CAN-18-2245
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.
Sica A, Guarneri V, Gennari A
Cell Stress. 2019 Jul 1;3(9):284-294. doi: 10.15698/cst2019.09.197
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages.
Di Martile M
J Immunother Cancer. 8(1)doi: 10.1136/jitc-2019-000489
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL
Clin Cancer Res. 2018 Oct 23;25(3):1098-1112. doi: 10.1158/1078-0432.CCR-18-1133
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
Consonni FM
Front Immunol. 2019 May 3;10:949. doi: 10.3389/fimmu.2019.00949
Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells.
Travelli C
Cancer Res. 2019 Feb 18;79(8):1938-1951. doi: 10.1158/0008-5472.CAN-18-1544